Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Subscribe
0 Comments
Oldest